© 2018 LP-DG® Science

Exit.st0{fill:none;stroke:#FFFFFF;stroke-width:2;stroke-linecap:round;stroke-linejoin:round;stroke-miterlimit:10;} .st1{fill:none;stroke:#00d9ff;stroke-width:1;enable-background:new;} .st2{fill:none;stroke:#FFFFFF;stroke-width:1;enable-background:new;}
/front/assets/b0_bg.b9f56.png
/front/assets/b1.4d847.png
/front/assets/b2.06d15.png
/front/assets/b3.e5655.png
/front/assets/b4.6dac4.png
/front/assets/b5.2ecb4.png
/front/assets/b6.feb5a.png
/front/assets/b7.9e3a3.png
/front/assets/b8.f130a.png
/front/assets/b9.660ae.png
/front/assets/b10.47360.png
/front/assets/b11.f3d7e.png
/front/assets/b12.a0e95.png
Detection Probiotic's DNA of Lactobacillus paracasei in Healthy Human Faeces
DOI: 10.9734/JPRI/2018/44636

AIMS:
To examine the DNA abundance of the probiotic bacteria (Lactobacillus paracasei) in the faeces of healthy adults after one month of its consumption and to determine the antimicrobial susceptibility profile of this bacteria.

STUDY DESIGN:
Thirty apparently healthy adults were examined for the presence of probiotic bacteria DNA in their faecal samples over a period of one month after one week of probiotic consumption.

PLACE AND DURATION:
Department of Pathology and Microbiology, School of Medicine, The University of Jordan, Amman, Jordan, Between July 2017 and January 2018

RESULTS:
L. paracasei DNA detected in 90% of these adults within a week of probiotic consumption, whereas after stopping the probiotic consumption, L. paracasei DNA was detected only in 10% and 6% of the faecal samples after one and two weeks, respectively. Minimal side effects were recorded among these volunteers’ adults. L. paracasei was susceptible to ampicillin, chloramphenicol, clindamycin, erythromycin, imipenem and piperacillin–tazobactam, intermediate Original Research Article Altaha et al.; JPRI, 23(6): 1-9, 2018; Article no.JPRI.44636 2 susceptible to levofloxacin and ciprofloxacin and resistant to amikacin, aztreonam, ceftazidime, gentamicin, oxacillin, meropenem and vancomycin.

CONCLUSION:
The consumption of probiotic L. paracasei for one week, resulted in a limited colonisation capacity in the human intestine, therefore, we recommend longer administration period. The susceptibility patterns of the probiotic bacteria L. paracasei should be considered when it will be administrated during antibiotic treatment.

Authors
Baraa M. Altaha , Jamal Wadi and Asem A. Shehabi*

Cookie Policy

This website uses technical and profiling cookies collecting data in aggregate form. By closing this banner, scrolling this page or clicking any of its elements you consent to the use of cookies.

Healthcare professionals

Part of the information contained in this website is exclusively addressed to healthcare professionals. Please confirm that you are a healthcare professional. Are you a healthcare professional?

Yes, I am
No, I am not
Content to third part

This website contains links/references to third-party websites. By such links, SOFAR does not provide any guarantee nor gives its approval to their contents and quality. SOFAR does not have and does not accept any responsibility for the contents or the availability of such websites; SOFAR does not accept any liability for damage or injury resulting from the use of such contents, of whatever form. Users access such websites at their own risk. The information contained in this website is for information purposes only and not for diagnostic or therapeutic purposes. Thus, it does not substitute in any way medical and /or expert or other healthcare professionals or specialists ‘advice.

Duly noted